Autor: |
Incorvaia, Lorena, Dimino, Alessandra, Algeri, Laura, Brando, Chiara, Magrin, Luigi, De Luca, Ida, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Bonasera, Annalisa, Bazan Russo, Tancredi Didier, Li Pomi, Federica, Peri, Marta, Gristina, Valerio, Galvano, Antonio, Giuffrida, Dario, Fazio, Ivan, Toia, Francesca, Cordova, Adriana, Florena, Ada Maria, Giordano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe |
Přispěvatelé: |
Incorvaia, Lorena, Dimino, Alessandra, Algeri, Laura, Brando, Chiara, Magrin, Luigi, De Luca, Ida, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Bonasera, Annalisa, Bazan Russo, Tancredi Didier, Li Pomi, Federica, Peri, Marta, Gristina, Valerio, Galvano, Antonio, Giuffrida, Dario, Fazio, Ivan, Toia, Francesca, Cordova, Adriana, Florena, Ada Maria, Giordano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Frontiers in Oncology. 13 |
ISSN: |
2234-943X |
DOI: |
10.3389/fonc.2023.1141500 |
Popis: |
BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with avelumab as first-line treatment. The study population included the patients treated from February 2019 to October 2022 in an Italian referral center for rare tumors. Clinico-pathological characteristics, BMI, laboratory parameters (NLR and platelet count), and response to avelumab were analyzed from a MCC System database prospectively collected.ResultsThirty-two (32) patients were included. Notably, the presence of pre-treatment BMI ≥ 30 was significantly associated with longer PFS [BMI < 30 Group: median PFS, 4 months (95% CI: 2.5-5.4); BMI ≥ 30 Group: median PFS, not reached; pConclusionTo our knowledge, this is the first study that investigates the predictive role of BMI in MCC patients. Our data were consistent with the clinical observation of improved outcomes in obese patients across other tumor types. Thus, advanced age, a weakened immune system, and the obesity-associated “inflammaging”, are key factors that could impact the cancer immune responses of mMCC patients. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|